GAVRETO

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Ecuador, Estonia, France, Ireland, Israel, Italy, Lithuania, Poland, Romania.

Active ingredients

The drug GAVRETO contains one active pharmaceutical ingredient (API):

1	Pralsetinib UNII 1WPE73O1WV - PRALSETINIB
	Pralsetinib is a potent protein kinase inhibitor that selectively targets oncogenic RET fusions (KIF5BRET and CCDC6-RET). In non-small cell lung cancer (NSCLC), RET fusions are one of the main oncogenic drivers.
	Read more about Pralsetinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
GAVRETO Hard capsule	MPI, EU: SmPC	European Medicines Agency (EU)
GAVRETO Capsule	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EX23		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX23

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	6644-MEE-1021
EE	Ravimiamet	1867765, 1867776, 1867787
FR	Base de données publique des médicaments	67194402
IL	מִשְׂרַד הַבְּרִיאוּת	9015, 9016, 9017
IT	Agenzia del Farmaco	049771013, 049771025, 049771037
LT	Valstybinė vaistų kontrolės tarnyba	1093820, 1093821, 1093822
PL	Rejestru Produktów Leczniczych	100460685
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68296001, W68296002
US	FDA, National Drug Code	72064-210